Kuzari Group

Kuzari Group, LLC is a private equity and venture capital firm based in New York, specializing in investments in middle and lower middle market businesses. Founded in 2009, the firm focuses on full or partial buy-outs, growth capital, and strategic acquisitions, typically seeking to take a majority stake in its portfolio companies. Kuzari Group manages a diverse portfolio of equity and debt investments on behalf of its partners and investors, targeting various industries and investment scenarios.

Sang Cho

Partner

3 past transactions

ONA

Acquisition in 2015
ONA Designs International, LLC specializes in handcrafted premium bags and accessories tailored for photographers. Founded in 2010 and based in New York, the company offers a diverse range of products, including messenger bags, shoulder bags, rolling bags, briefcases, backpacks, and small goods. ONA's offerings are designed to protect essential photography equipment while providing style and functionality. The products are available through various retail stores and an online platform, allowing the company to reach customers both domestically and internationally.

Precipio Diagnostics

Series B in 2013
Precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. Our goal is to assist oncologists in providing the best care for their patients. At the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the Yale School of Medicine. At Precipio, our customers and their patients benefit from the most accurate, expert diagnosis.

New Haven Pharmaceuticals

Series A in 2012
New Haven Pharmaceuticals (NHP) is a specialty pharmaceuticals company focused on developing proprietary prescription medications that leverage currently marketed drugs and generally recognized as safe (GRAS) active pharmaceutical ingredients for therapeutic applications with substantial market potential. The company is advancing a product pipeline that features innovative, oral, controlled-release technologies, enhancing dosing accuracy, safety, efficacy, and patient convenience. NHP's research is supported by intellectual property licensed from Yale University, allowing for the development of new therapeutic indications using established compounds.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.